Cytokinetics Inc.
CYTK Real Time Price USDRecent trades of CYTK by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CYTK's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Apr 21, 2025 Issue: Health Issues
-
$10,000 Jan 16, 2025 Issue: Health Issues
Estimated quarterly lobbying spending
CYTK Revenue by Segment or Geography
| Segment | Revenue | % of All Segments |
|---|---|---|
| Research and Development | $1.6M | 100.00% |
As of: Q1 2025 (03/31/2025)
Click on a segment for historical trends.New patents grants
-
Patent Title: Compounds, compositions and methods Apr. 01, 2025
-
Patent Title: Process for preparing aficamten Mar. 11, 2025
-
Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Feb. 11, 2025
-
Patent Title: Cardiac sarcomere inhibitors Jan. 07, 2025
-
Patent Title: Cardiac sarcomere inhibitors Aug. 20, 2024
-
Patent Title: Methods for treating heart failure by administering cardiac sarcomere activators May. 21, 2024
-
Patent Title: Bicyclic 1,4-diazepanones and therapeutic uses thereof May. 14, 2024
-
Patent Title: Cardiac sarcomere inhibitors Apr. 23, 2024
-
Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Apr. 16, 2024
-
Patent Title: Cardiac sarcomere inhibitors Apr. 09, 2024
-
Patent Title: Process for preparing aficamten Mar. 19, 2024
-
Patent Title: Cardiac sarcomere inhibitors Mar. 05, 2024
-
Patent Title: Heterocyclic compounds and their uses Jan. 30, 2024
-
Patent Title: Tetrahydroisoquinoline derivatives Oct. 25, 2022
-
Patent Title: Cardiac sarcomere inhibitors Oct. 18, 2022
-
Patent Title: Salt of omecamtiv mecarbil and process for preparing salt Oct. 18, 2022
-
Patent Title: Salts and crystal forms of omecamtiv mecarbil Oct. 11, 2022
-
Patent Title: Cardiac sarcomere inhibitors Aug. 16, 2022
-
Patent Title: Heterocyclic compounds and their uses Jul. 12, 2022
-
Patent Title: Amino-pyrimidine skeletal muscle modulators Jun. 28, 2022
-
Patent Title: Bisamide sarcomere activating compounds and uses thereof Apr. 12, 2022
-
Patent Title: Process for the preparation of an amino-pyrimidine and intermediates thereof Oct. 12, 2021
-
Patent Title: Compounds, compositions and methods Apr. 13, 2021
-
Patent Title: Cardiac sarcomere inhibitors Nov. 17, 2020
-
Patent Title: Methods for preparing substituted imidazo[4,5-b]pyrazines Sep. 08, 2020
-
Patent Title: Amino-pyrimidine skeletal muscle modulators Sep. 08, 2020
-
Patent Title: Compounds, compositions and methods Aug. 20, 2019
-
Patent Title: Combination als therapy Apr. 30, 2019
-
Patent Title: Amino-pyrimidine skeletal muscle modulators Apr. 30, 2019
-
Patent Title: Substituted pyridazines as skeletal muscle modulators Sep. 18, 2018
-
Patent Title: Compounds, compositions and methods Jul. 31, 2018
-
Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Jun. 12, 2018
-
Patent Title: Amino-pyrimidine skeletal muscle modulators Aug. 15, 2017
-
Patent Title: Substituted pyridazines as skeletal muscle modulators Mar. 28, 2017
-
Patent Title: Certain heterocycles, compositions thereof, and methods for their use Mar. 08, 2016
-
Patent Title: Compounds, compositions and methods Oct. 06, 2015
-
Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Sep. 15, 2015
-
Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Apr. 28, 2015
-
Patent Title: Amino-pyridazine skeletal muscle modulators Mar. 03, 2015
-
Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Feb. 24, 2015
-
Patent Title: Certain chemical entities, compositions, and methods Nov. 25, 2014
-
Patent Title: Ureas and their use in the treatment of heart failure Oct. 28, 2014
-
Patent Title: Certain chemical entities, compositions and methods Oct. 28, 2014
-
Patent Title: Imidazole-benzamide anti-cancer agents Jul. 08, 2014
-
Patent Title: Certain heterocycles, compositions thereof, and methods for their use Jun. 24, 2014
-
Patent Title: Certain chemical entities, compositions, and methods Jun. 24, 2014
-
Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use May. 06, 2014
-
Patent Title: Certain heterocycles, compositions thereof, and methods for their use Apr. 01, 2014
-
Patent Title: Methods and compositions utilizing quinazolinones Feb. 25, 2014
-
Patent Title: Certain chemical entities, compositions, and methods Feb. 18, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CYTK
Recent picks made for CYTK stock on CNBC
ETFs with the largest estimated holdings in CYTK
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CYTK stock a Buy, Sell, or Hold?
- What is the price target for $CYTK stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CYTK stock?
- Who owns the most shares of $CYTK stock?
- What funds own $CYTK stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CYTK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.